Latest News
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets.
3 Breakout Growth Stocks to Buy for the Long Haul
These three have had big-time share gains backed up by breakthrough science.
September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the flow of Tuesday's sell-off
3 Healthcare Stocks That Are Beating the Market
Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022
These three healthcare stocks have defied the 2022 bear market.
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
The biotech's second-quarter earnings report is a big hit with shareholders.
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
-- Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a...
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
-- Reimbursed early access program allows for patients in France to receive setmelanotide for treatment of obesity and control of hunger associated with...
NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm...
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
--All evaluable patients (N=11) achieved BMI decrease of more than 5 percent at 16 weeks on setmelanotide therapy-- --17.2 percent mean reduction in BMI...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to...
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to...
Morning Markets September S&P 500 futures (ESU22 ) this morning are up by +1.00%. Stock indexes futures are recovering from Thursday’s rout that took the S&P 500 down to a 1-1/2 year low. Today brings the quarterly expiration of stock futures and options known as triple witching. The market is...
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million
Extends Cash Runway into 2H 2024...